Tyra Biosciences, Inc. (TYRA)
After hours:
| Previous Close | 18.53 |
| Open | 19.07 |
| Bid | 17.77 x 100 |
| Ask | 17.88 x 200 |
| Day's Range | 17.43 - 19.24 |
| 52 Week Range | 10.38 - 20.67 |
| Volume | |
| Avg. Volume | 129,705 |
| Market Cap | 937.552M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent corporate progress.
- PR Newswire
Tyra Biosciences to Present at Upcoming Investor Conferences
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:
- PR Newswire
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that Todd Harris, CEO of TYRA, will present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 2pm ET. The conference is being held in a virtual format.
